Dash Acquisitions Inc. has a $280,000 stake in Eli Lilly and Company (NYSE:LLY)

Dash Acquisitions Inc. raised its stake in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 12.3% in the 1st quarter, according to its latest 13F filing with the Securities and Exchange Commission. The firm now owns 373 shares of the company’s stock after purchasing an additional 41 shares during the quarter. Dash Acquisitions Inc.’s stake in Eli Lilly and Company was worth $280,000 at the end of the last reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings in the stock. Vanguard Group Inc. increased its holdings in Eli Lilly and Company by 0.9% in the 3rd quarter. Vanguard Group Inc. now owns 70,575,602 shares of the company’s stock worth $37,908,273,000 after purchasing an additional 659,838 shares in the last quarter. Capital World Investors increased its holdings in Eli Lilly and Company by 0.3% in the 4th quarter. Capital World Investors now owns 26,949,773 shares of the company’s stock worth $15,709,466,000 after purchasing an additional 89,720 shares in the last quarter. Morgan Stanley increased its holdings in Eli Lilly and Company by 0.7% in the 3rd quarter. Morgan Stanley now owns 12,545,572 shares of the company’s stock valued at $6,738,605,000 after purchasing an additional 83,915 shares during the last quarter. Norges Bank bought a new stake in Eli Lilly and Company in the fourth quarter valued at approximately $5,992,890,000. Finally, Capital Research Global Investors increased its position in Eli Lilly and Company by 4.5% during the fourth quarter. Capital Research Global Investors now owns 7,577,592 shares of the company’s stock valued at $4,417,120,000 after purchasing an additional 325,342 shares in the last quarter. 82.53% of the shares are owned by institutional investors.

Eli Lilly and Company Price Results

Shares of Eli Lilly and Company opened at $906.71 on Wednesday. The company has a market capitalization of $861.75 billion, a price-to-earnings ratio of 133.54, a PEG ratio of 1.97 and a beta of 0.41. The company has a current ratio of 1.35, a current ratio of 1.03 and a debt-to-equity ratio of 1.90. Eli Lilly and Company has a 12-month low of $434.34 and a 12-month high of $916.83. The stock’s 50-day moving average is $818.06, and its 200-day moving average is $743.26.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last released its quarterly financial results on Monday, May 6. The company reported $2.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.53 by $0.05. The company had revenue of $8.77 billion for the quarter, compared to the consensus estimate of $8.94 billion. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The company’s quarterly revenue increased 26.0% year-over-year. During the same period in the prior year, the company posted $1.62 EPS. Equity research analysts expect Eli Lilly and Company to post $13.76 EPS for the current year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 10. Investors of record on Thursday, August 15 will receive a dividend of $1.30 per share. This represents a dividend of $5.20 annualized and a yield of 0.57%. The ex-dividend date is Thursday, August 15. Eli Lilly and Company’s dividend payout ratio is 76.58%.

Insiders are betting

In other news, CAO Donald A. Zakrowski sold 750 shares of the company’s stock in a transaction that occurred on Monday, June 3. The shares were sold at an average price of $819.47, for a total transaction amount of $614,602.50. Following the transaction, the chief financial officer now directly owns 7,130 shares of the company’s stock, valued at $5,842,821.10. The sale was disclosed in legal documents filed with the Securities & Exchange Commission, which can be accessed through the SEC’s website . In related news, CAO Donald A. Zakrowski sold 750 shares of the company’s stock in a transaction that occurred on Monday, June 3. The shares were sold at an average price of $819.47, for a total transaction amount of $614,602.50. Following the sale, the chief financial officer now directly owns 7,130 shares of the company’s stock, valued at $5,842,821.10. The sale was disclosed in a document filed with the Securities and Exchange Commission, which is available at this link . Additionally, Executive Vice President John Norton sold 7,056 shares of Eli Lilly and Company stock in a transaction on Monday, June 3. The shares were sold for an average price of $819.38, for a total value of $5,781,545.28. Following the completion of the transaction, the Executive Vice President now directly owns 25,428 shares of the company’s stock, valued at $20,835,194.64. Disclosure of that sale can be found here . Insiders sold 849,894 shares of the company’s stock valued at $727,475,118 during the last quarter. 0.13% of the stock is currently owned by corporate insiders.

Changes in analyst ratings

Several analysts have recently commented on the stock. Bank of America reissued a “buy” rating and set a $1,000.00 price target on shares of Eli Lilly and Company in a research report on Monday, June 24. Citigroup raised their price target on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the stock a “buy” rating in a research note on Tuesday, April 2. Argus raised their price target on Eli Lilly and Company from $770.00 to $840.00 and gave the company a “buy” rating in a research report on Tuesday, May 14. BMO Capital Markets raised their price target on Eli Lilly and Company from $900.00 to $1,001.00 and gave the company an “outperform” rating in a research report on Wednesday, May 1. Finally, Truist Financial reaffirmed a “buy” rating and set a $1,000.00 price target (up from $892.00) on shares of Eli Lilly and Company in a research report on Tuesday, June 25. Three investment analysts have rated the stock a “hold,” while seventeen have given it a “buy” rating. The stock has an average rating of “Moderate Buy” and an average price target of $812.72, according to data from MarketBeat.

Check out our latest report on LLY

Eli Lilly and company profile

(Free report)

Eli Lilly and Company discovers, develops, and markets pharmaceutical products for people worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Featured Stories

Get daily news and reviews about Eli Lilly and Company – Enter your email address below to receive a concise summary of the latest news and analyst ratings for Eli Lilly and Company and related companies in MarketBeat.com’s FREE daily newsletter.